Abstract
Objectives: To review the evidence of the involvement of the Wnt signalling pathway in mood disorders and in the action of drugs used to treat these disorders. Methods: We performed a careful PubMed search using as keywords all possible terms relevant to the Wnt pathway and crossing them with each of four areas, i.e., developmental effects, behavioural effects, mood disorders, and drugs used in their treatment. Papers were selected on the basis of their content and their data used for discussion. Results: Neurodevelopmental and behavioural data point to the possibility of involvement of the Wnt pathway in the pathophysiology of mood disorders. Clinical and post-mortem data are not sufficient to corroborate a definite role for Wnt alterations in any mood disorder. Combining genetic and pharmacological data, we may state that glycogen synthase kinase is the key molecule in bipolar disorder, as it is connected with many other signalling pathways that were shown to be involved in mood disorders, while Wnt molecules in the hippocampus appear to be mainly involved in depressive disorders. Conclusions: Altered Wnt signalling may play a role in the pathophysiology of mood disorders, although not a central one. It is premature to draw conclusions regarding the possible usefulness of Wnt manipulations in the treatment of mood disorders.
| Original language | English |
|---|---|
| Pages (from-to) | 239-253 |
| Number of pages | 15 |
| Journal | Current Neuropharmacology |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2012 |
Fingerprint
Keywords
- Antidepressant Drugs
- Antipsychotic Drugs
- Bipolar Disorder
- Major Depression
- Mood Disorders
- Mood Stabilising Agents
- Wingless (Wnt) signalling
ASJC Scopus subject areas
- Clinical Neurology
- Pharmacology (medical)
- Pharmacology
- Neurology
- Psychiatry and Mental health
Cite this
The wnt pathway in mood disorders. / Sani, Gabriele; Napoletano, Flavia; Forte, Alberto Maria; Kotzalidis, Giorgio D.; Panaccione, Isabella; Porfiri, Giulio Maria; Simonetti, Alessio; Caloro, Matteo; Girardi, Nicoletta; Telesforo, Carla Ludovica; Serra, Giulia; Romano, Silvia; Manfredi, Giovanni; Savoja, Valeria; Tamorri, Stefano Maria; Koukopoulos, Alexia E.; Serata, Daniele; Rapinesi, Chiara; Casale, Antonio Del; Nicoletti, Ferdinando; Girardi, Paolo.
In: Current Neuropharmacology, Vol. 10, No. 3, 2012, p. 239-253.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The wnt pathway in mood disorders
AU - Sani, Gabriele
AU - Napoletano, Flavia
AU - Forte, Alberto Maria
AU - Kotzalidis, Giorgio D.
AU - Panaccione, Isabella
AU - Porfiri, Giulio Maria
AU - Simonetti, Alessio
AU - Caloro, Matteo
AU - Girardi, Nicoletta
AU - Telesforo, Carla Ludovica
AU - Serra, Giulia
AU - Romano, Silvia
AU - Manfredi, Giovanni
AU - Savoja, Valeria
AU - Tamorri, Stefano Maria
AU - Koukopoulos, Alexia E.
AU - Serata, Daniele
AU - Rapinesi, Chiara
AU - Casale, Antonio Del
AU - Nicoletti, Ferdinando
AU - Girardi, Paolo
PY - 2012
Y1 - 2012
N2 - Objectives: To review the evidence of the involvement of the Wnt signalling pathway in mood disorders and in the action of drugs used to treat these disorders. Methods: We performed a careful PubMed search using as keywords all possible terms relevant to the Wnt pathway and crossing them with each of four areas, i.e., developmental effects, behavioural effects, mood disorders, and drugs used in their treatment. Papers were selected on the basis of their content and their data used for discussion. Results: Neurodevelopmental and behavioural data point to the possibility of involvement of the Wnt pathway in the pathophysiology of mood disorders. Clinical and post-mortem data are not sufficient to corroborate a definite role for Wnt alterations in any mood disorder. Combining genetic and pharmacological data, we may state that glycogen synthase kinase is the key molecule in bipolar disorder, as it is connected with many other signalling pathways that were shown to be involved in mood disorders, while Wnt molecules in the hippocampus appear to be mainly involved in depressive disorders. Conclusions: Altered Wnt signalling may play a role in the pathophysiology of mood disorders, although not a central one. It is premature to draw conclusions regarding the possible usefulness of Wnt manipulations in the treatment of mood disorders.
AB - Objectives: To review the evidence of the involvement of the Wnt signalling pathway in mood disorders and in the action of drugs used to treat these disorders. Methods: We performed a careful PubMed search using as keywords all possible terms relevant to the Wnt pathway and crossing them with each of four areas, i.e., developmental effects, behavioural effects, mood disorders, and drugs used in their treatment. Papers were selected on the basis of their content and their data used for discussion. Results: Neurodevelopmental and behavioural data point to the possibility of involvement of the Wnt pathway in the pathophysiology of mood disorders. Clinical and post-mortem data are not sufficient to corroborate a definite role for Wnt alterations in any mood disorder. Combining genetic and pharmacological data, we may state that glycogen synthase kinase is the key molecule in bipolar disorder, as it is connected with many other signalling pathways that were shown to be involved in mood disorders, while Wnt molecules in the hippocampus appear to be mainly involved in depressive disorders. Conclusions: Altered Wnt signalling may play a role in the pathophysiology of mood disorders, although not a central one. It is premature to draw conclusions regarding the possible usefulness of Wnt manipulations in the treatment of mood disorders.
KW - Antidepressant Drugs
KW - Antipsychotic Drugs
KW - Bipolar Disorder
KW - Major Depression
KW - Mood Disorders
KW - Mood Stabilising Agents
KW - Wingless (Wnt) signalling
UR - http://www.scopus.com/inward/record.url?scp=84867564968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867564968&partnerID=8YFLogxK
U2 - 10.2174/157015912803217279
DO - 10.2174/157015912803217279
M3 - Article
C2 - 23449817
AN - SCOPUS:84867564968
VL - 10
SP - 239
EP - 253
JO - Current Neuropharmacology
JF - Current Neuropharmacology
SN - 1570-159X
IS - 3
ER -